⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) Institutional Ownership

13F filers reported holding 19.7% of Biomarin Pharmaceutical (BMRN) shares as of Sep 30, 2026, across 308 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
19.7%
Sep 30, 2026
13F filers
308
quarter ended Sep 30, 2026
13F value
$2.3B
38.1M shares
Quarter's fund flow
Mild accumulation
46 new · 27 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (46 new · 107 increased · 86 reduced · 27 closed · 42 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 308 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 30, 2026Friberg Gregory REVP, Chief R&D OfficerDisposed · Tax withholding4,086$60.00↗
Sep 10, 2026Plenge Robert MdirectorAcquired · Grant / award6,140—↗
Sep 2, 2026Davis George EricEVP, Chief Legal OfficerDisposed · Open-market sale17,557$66.28↗
Jun 2, 2026Countouriotis AthenadirectorAcquired · Grant / award7,490—↗
Jun 2, 2026Walbert Timothy PdirectorAcquired · Grant / award7,490—↗
Jun 2, 2026Ho MaykindirectorAcquired · Grant / award7,490—↗
Jun 2, 2026HOMBACH ROBERT J.directorAcquired · Grant / award7,490—↗
Jun 2, 2026Enyedy Mark JdirectorAcquired · Grant / award7,490—↗
Jun 2, 2026Dere Willard HdirectorAcquired · Grant / award7,490—↗
Jun 2, 2026CLARK IAN TdirectorAcquired · Grant / award7,490—↗
Jun 2, 2026Bodem Barbara W.directorAcquired · Grant / award7,490—↗
Jun 2, 2026ANDERSON ELIZABETH MdirectorAcquired · Grant / award7,490—↗
May 20, 2026Hubbard CristinEVP, Chief Commercial OfficerDisposed · Tax withholding2,318$50.20↗
May 7, 2026Friberg Gregory REVP, Chief R&D OfficerDisposed · Open-market sale3,281$53.85↗
Mar 18, 2026Davis George EricEVP, Chief Legal OfficerDisposed · Tax withholding1,273$56.05↗
Mar 17, 2026Guyer Charles GregEVP, Chief Technical OfficerDisposed · Tax withholding1,693$56.05↗
Mar 17, 2026Mueller BrianEVP, Chief Financial OfficerDisposed · Tax withholding2,117$56.05↗
Mar 17, 2026Hardy AlexanderChief Executive OfficerDisposed · Tax withholding4,252$56.05↗
Mar 17, 2026Hubbard CristinEVP, Chief Commercial OfficerDisposed · Tax withholding1,245$56.05↗
Mar 17, 2026Friberg Gregory REVP, Chief R&D OfficerDisposed · Tax withholding1,629$56.05↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Biomarin Pharmaceutical do institutions hold?

13F filers reported holding 19.7% of Biomarin Pharmaceutical's shares as of Sep 30, 2026, across 308 filers.

How many 13F filers hold Biomarin Pharmaceutical?

Biomarin Pharmaceutical was held by 308 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.